PL376882A1 - Szczepionka - Google Patents

Szczepionka

Info

Publication number
PL376882A1
PL376882A1 PL376882A PL37688203A PL376882A1 PL 376882 A1 PL376882 A1 PL 376882A1 PL 376882 A PL376882 A PL 376882A PL 37688203 A PL37688203 A PL 37688203A PL 376882 A1 PL376882 A1 PL 376882A1
Authority
PL
Poland
Prior art keywords
vaccine
Prior art date
Application number
PL376882A
Other languages
English (en)
Inventor
Sara Brett
Paul Andrew Hamblin
Louise Ogilvie
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL376882A1 publication Critical patent/PL376882A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL376882A 2002-11-15 2003-11-13 Szczepionka PL376882A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0226722.7A GB0226722D0 (en) 2002-11-15 2002-11-15 Vaccine

Publications (1)

Publication Number Publication Date
PL376882A1 true PL376882A1 (pl) 2006-01-09

Family

ID=9947928

Family Applications (2)

Application Number Title Priority Date Filing Date
PL376882A PL376882A1 (pl) 2002-11-15 2003-11-13 Szczepionka
PL376967A PL376967A1 (pl) 2002-11-15 2003-11-13 Szczepionka przeciw HCV

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL376967A PL376967A1 (pl) 2002-11-15 2003-11-13 Szczepionka przeciw HCV

Country Status (21)

Country Link
US (4) US20060246090A1 (pl)
EP (2) EP1560844A1 (pl)
JP (2) JP2006524181A (pl)
KR (2) KR20050085010A (pl)
CN (2) CN1738834A (pl)
AR (1) AR041964A1 (pl)
AU (2) AU2003288072A1 (pl)
BR (2) BR0316244A (pl)
CA (2) CA2504654A1 (pl)
CO (1) CO5700833A2 (pl)
GB (1) GB0226722D0 (pl)
IS (2) IS7830A (pl)
MA (2) MA27700A1 (pl)
MX (2) MXPA05005202A (pl)
NO (2) NO20052136L (pl)
NZ (2) NZ539998A (pl)
PL (2) PL376882A1 (pl)
RU (2) RU2363492C2 (pl)
TW (1) TW200502246A (pl)
WO (2) WO2004046175A1 (pl)
ZA (2) ZA200503803B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CN101437964B (zh) * 2004-10-18 2012-06-13 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
JP5405832B2 (ja) * 2006-01-04 2014-02-05 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｈｃｖ特異的なｔ細胞の活性化
ES2387321T3 (es) 2006-03-09 2012-09-20 Transgene Sa Proteína de fusión no estructural del virus de la hepatitis C
US20100047266A1 (en) * 2006-07-27 2010-02-25 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
AU2007345768B2 (en) * 2006-07-27 2013-08-01 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
KR100759106B1 (ko) * 2007-02-14 2007-09-19 이화여자대학교 산학협력단 초미세 전기기계 시스템 미러에서 미러 판을 정전 구동부와 결합하는 방법
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009131681A2 (en) * 2008-04-22 2009-10-29 Rutgers, The State University Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
EP2331123A4 (en) * 2008-07-24 2012-11-07 Aduro Biotech COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
CN101748151B (zh) * 2008-12-19 2012-10-17 深圳市源兴生物医药科技有限公司 一种重组人丙肝病毒抗原腺病毒载体及其应用
JP2010168288A (ja) * 2009-01-20 2010-08-05 Yokohama City Univ 最適化した抗原遺伝子の使用によるウイルスワクチンの免疫原性の増強
EP2496609A4 (en) 2009-11-03 2013-05-08 Ligocyte Pharmaceuticals Inc CHIMERIC RSV-F POLYPEPTIDE AND VLPS ON LENTIVIREN OR ALPHA RETROVIRUS GAG BASE
CN102233137B (zh) * 2010-04-30 2013-02-20 北京凯因科技股份有限公司 一种用于治疗乙型肝炎的重组质粒dna疫苗组合物
EP2958994B1 (en) 2013-02-21 2019-05-29 Turnstone Limited Partnership Vaccine composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
HUT77870A (hu) * 1994-10-05 1998-09-28 Apollon, Inc. Hepatitiszvírus elleni vakcinák
IL118364A0 (en) * 1995-05-22 1996-09-12 Bionova Corp A hepatitis C virus-derived composition methods for the preparation thereof and assays for the detection of hepatitis C virus
CA2257137A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
WO2001004149A1 (en) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis c virus proteins
AU1236801A (en) * 1999-10-27 2001-05-08 Chiron Corporation Activation of hcv-specific t cells
EP1233982B1 (en) * 1999-11-24 2007-10-24 Novartis Vaccines and Diagnostics, Inc. Novel hcv non-structural polypeptide
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine

Also Published As

Publication number Publication date
RU2323744C2 (ru) 2008-05-10
NO20052136D0 (no) 2005-05-02
RU2363492C2 (ru) 2009-08-10
IS7831A (is) 2005-04-28
CN1738833A (zh) 2006-02-22
BR0316291A (pt) 2005-10-11
WO2004046176A1 (en) 2004-06-03
KR20050085009A (ko) 2005-08-29
TW200502246A (en) 2005-01-16
KR20050085010A (ko) 2005-08-29
GB0226722D0 (en) 2002-12-24
AU2003288084A1 (en) 2004-06-15
US20090232847A1 (en) 2009-09-17
MA27700A1 (fr) 2006-01-02
MXPA05005202A (es) 2006-01-27
WO2004046175A1 (en) 2004-06-03
AR041964A1 (es) 2005-06-01
EP1560845A1 (en) 2005-08-10
JP2006524181A (ja) 2006-10-26
NO20052136L (no) 2005-07-11
CN1738834A (zh) 2006-02-22
ZA200503802B (en) 2006-08-30
BR0316244A (pt) 2005-10-04
IS7830A (is) 2005-04-28
CO5700833A2 (es) 2006-11-30
PL376967A1 (pl) 2006-01-23
RU2005113691A (ru) 2006-01-27
NO20052149D0 (no) 2005-05-02
CA2504715A1 (en) 2004-06-03
US20060246090A1 (en) 2006-11-02
US20060135451A1 (en) 2006-06-22
MA27699A1 (fr) 2006-01-02
EP1560844A1 (en) 2005-08-10
MXPA05005203A (es) 2006-01-27
US20090104231A1 (en) 2009-04-23
NO20052149L (no) 2005-07-11
JP2006518331A (ja) 2006-08-10
RU2005113692A (ru) 2006-01-27
NZ539998A (en) 2008-04-30
NZ539999A (en) 2008-03-28
CA2504654A1 (en) 2004-06-03
ZA200503803B (en) 2006-08-30
AU2003288072A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
GB0213622D0 (en) Vaccine Corporation
GB0202901D0 (en) Novel vaccine
GB0226722D0 (en) Vaccine
IL173921A0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0225788D0 (en) Vaccine
GB0225786D0 (en) Vaccine
GB0212046D0 (en) Vaccines
GB0228715D0 (en) Vaccine
GB0218921D0 (en) Novel vaccine
GB0305794D0 (en) Vaccine
GB0209878D0 (en) Vaccine
GB0330079D0 (en) Vaccine
PL376534A1 (pl) Szczepionka
GB0305793D0 (en) Vaccine
GB0212036D0 (en) Vaccines
GB0206595D0 (en) Vaccine
IL156434A0 (en) Vaccine
GB0226179D0 (en) Vaccine
GB0223355D0 (en) Vaccine
GB0220211D0 (en) Vaccine
GB0213364D0 (en) Vaccine
GB0229594D0 (en) Vaccine
GB0230170D0 (en) Vaccine
GB0228714D0 (en) Vaccine

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)